TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

SHANGHAI (Reuters) -Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior ...

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments.

Bengaluru: Biocon Biologics Ltd ., a fully integrated global biosimilars company and a subsidiary of Biocon Ltd ., has ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

Biotechnology firm Biocon Ltd on Thursday said its board has approved the acquisition of optionally convertible debentures of ...

Biotechnology firm Biocon Ltd announces its board's approval to acquire optionally convertible debentures of its subsidiary ...

Biocon Ltd acquires Biocon Biologics debentures from Goldman Sachs for USD 198.5 million. The acquisition involves 1,125 ...

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows ...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL) , a fully integrated ...